AI Financial Corporation Rebrands Its Biotech Business as Drew Therapeutics in Honor of Andrew Witkoff, Who Succumbed to Opioid Addiction in 2011
Key Highlights
- ➤AI Financial rebrands Alyea Therapeutics as Drew Therapeutics Corporation
- ➤Drew Therapeutics will become a separate, independent public company
- ➤Lead LDN program for CRPS has FDA orphan drug designation
- ➤Drew develops non-opioid chronic-pain treatments, including the Drew Clear Patch
- ➤CEO Tony Isaac says further strategic initiatives are coming
Expert Statements
Tony Isaac, CEO of AI Financial Corporation
“The story of Andrew Witkoff reinforces our commitment to developing non-addictive painkillers, reducing pain and saving lives.”
Tony Isaac, CEO of AI Financial Corporation
“Society, unfortunately, tends to deal with the crisis in cold statistics. But sheer numbers cannot convey the painful reality that each person who dies is a son or a daughter, a brother or a sister, or a beloved friend. Andrew Witkoff represents every person lost to opioids who could have been saved. He will be the voice for those who can no longer speak. In his name, we will advance the science of killing pain not people.”
Amol Soin, Head of Drew Therapeutics Corporation
“a moving reminder that scientific research into safer ways for treating pain is ultimately about saving lives.”
Zach Witkoff, Chairman of AI Financial Corporation
“I am hopeful that Drew’s name and memory will continue to inspire the development of life-saving alternatives to the addictive drugs that have destroyed thousands of lives. Opioids are non-partisan. They are an equal opportunity killer, destroying lives of people in both political parties, all races and social classes. It is a shocking fact that, although Americans make up only 5 percent of the world’s population, we consume 80% of the world’s oxycodone. This crisis must be addressed through heightened public awareness, an end to careless, and sometimes illegal, prescriptions of addicting pain-killers.”
Tony Isaac, CEO of AI Financial Corporation
“In the weeks ahead, we will roll out other important initiatives to activate further our strategic plans for the benefit of our stockholders. The markets will hear more from us - so, stay tuned.”
LAS VEGAS, NV / ACCESS Newswire / October 14, 2026 / Under the rallying cry "Out of Pain Comes Purpose," AI Financial Corporation (Nasdaq:AIFC)(FRA:5AR1) announced the rebranding of its biotech segment as "Drew Therapeutics Corporation." The new name honors Andrew Witkoff, brother of the company's chairman, who died of opioid overdose in 2011 at the young age of 22.
AI Financial is a leading fintech, specializing in agentic commerce. Its biotech segment has a robust pipeline of non-addictive treatments for pain and will become a separate, independent public company, as previously announced. AI Financial's CEO Tony Isaac expressed appreciation for "the honor of using Andrew's name as our brand." He said, "The story of Andrew Witkoff reinforces our commitment to developing non-addictive painkillers, reducing pain and saving lives."
Get started
Create a free account to read the full story.